Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis (Advances in Therapy, (2020), 37, 9, (4033-4042), 10.1007/s12325-020-01449-0)

Pietro Lampertico*, Stefan Mauss, Marcello Persico, Stephen T. Barclay, Steven Marx, Kristina Lohmann, Mark Bondin, Zhen Zhen Zhang, Fiona Marra, Pamela S. Belperio, Heiner Wedemeyer, Steven Flamm

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the original article, there is an error in Fig. 1. The correct Fig. 1 is given below: (Figure presented.).

Original languageEnglish (US)
Pages (from-to)4755-4756
Number of pages2
JournalAdvances in Therapy
Volume37
Issue number11
DOIs
StatePublished - Nov 1 2020

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis (Advances in Therapy, (2020), 37, 9, (4033-4042), 10.1007/s12325-020-01449-0)'. Together they form a unique fingerprint.

Cite this